1 | Abatacept | Abatacept [36] Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (ctla4-ig); Abatacept (iv); Abatacept (sc); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept active treatment; Abatacept delayed-onset treatment; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Device: abatacept combination product (acp); Double-blind abatacept; Drug: abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Orencia® (abatacept); Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; | [1] D03203 D03203 💬 |
[2] CD80, CD86 💬 |
Allograft rejection [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
2 | Adalimumab | Adalimumab [76] Adalimumab; Adalimumab (40 mg); Adalimumab (ada); Adalimumab (d2e7); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab - gp2017; Adalimumab - us licensed humira; Adalimumab 40 mg; Adalimumab 40 mg eow or ew; Adalimumab 40 mg sc every other week; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab and infliximab; Adalimumab humira; Adalimumab injection; Adalimumab injection [humira]; Adalimumab pfs and pen; Adalimumab prn; Adalimumab with methotrexate; Adalimumab, current formulation; Adalimumab, etanercept, golimumab or infliximab; Adalimumab, new formulation; Adalimumab, plus prednisone; Adalimumab, solution for injection 40 mg/ (0.8 ml) pre-filled syringe; Adalimumab-eu; Adalimumab-pfizer; Amgevita (adalimumab biosimilar ); Anti-tnf therapy (etanercept or adalimumab); Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Ct-p17 sc ai (adalimumab); Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Device: adalimumab delivered in current autoinjector; Device: adalimumab delivered in current syringe; Device: adalimumab delivered in physiolis autoinjector; Device: adalimumab delivered in physiolis syringe; Diagnostic test: adalimumab serum trough concentration; Diagnostic test: adalimumab trough concentration; Double-blind adalimumab; Etanercept or adalimumab; Fitc-adalimumab; Gp2017 (adalimumab biosimilar); Humira (adalimumab original); Humira (adalimumab); Humira (adalimumab) 40 mg in 0.4 ml s.c. injection; Humira (adalimumab) 40 mg s.c. injection; Humira (adalimumab) 40mg in 0.4 ml s.c. injection; Humira (adalimumab) 40mg in 0.4ml s.c.injection; Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira ® (adalimumab) 40mg/0.8ml pre-filled syringe; Humira® (adalimumab); Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Ol adalimumab 40 mg; Open-label adalimumab; Open-labeladalimumabrescue; Other: adalimumab; Other: adalimumab treatment; Other: lengthening adalimumab dosing interval; Other: measurement of drug (adalimumab/infliximab); Sb5 (proposed biosimilar to adalimumab); Start adalimumab in monotherapy; Tnf blockers (infliximab, adalimumab, etanercept); Treatment with adalimumab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | [1] D02597 D02597 💬 |
[1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
019 [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬 |
3 | Atorvastatin | Atorvastatin [9] Atorvastatin; Atorvastatin 10mg; Atorvastatin 20mg; Atorvastatin calcium; Atorvastatin tablet 20 mg; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Lisinopril, losartan, and atorvastatin; Untreated to atorvastatin treatment; | [3] D00258 D00258
D00887 D00887
D07474 D07474 💬 |
[1] HMGCR 💬 |
AMPK signaling pathway [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
013 [17] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 💬 |
4 | Bezafibrate | Bezafibrate [10] Bezafibrate; Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour udca therapy; Bezafibrate (drug); Bezafibrate (inn 3968); Bezafibrate 200 mg; Bezafibrate 400 mg; Bezafibrate ir; Bezafibrate sr; Bezafibrate, beza, bzf, bezalip; Bezafibrate, beza, bzf, bezalip mono; | [1] D01366 D01366 💬 |
[1] PPARA 💬 |
Adipocytokine signaling pathway [8] Adipocytokine signaling pathway, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway |
020 [6] 20, 93, 94, 160, 316, 324 💬 |
5 | BMS-986142 | Bms-986142 [6] Bms-986142; Bms-986142 200mg; Bms-986142 350mg; Bms986142; Methotrexate, leucovorin and bms-986142; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; | - |
- |
- |
046 [3] 46, 53, 160 💬 |
6 | Cholesterol | 3h-cholesterol bound to albumin [10] 3h-cholesterol bound to albumin; Cholesterol; Cholesterol supplementation; Crystalline cholesterol oil-based suspension; Egg substitute, without cholesterol; Egg yolk preparation with cholesterol; Lysosomal acid lipase, esterase cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa); Lysosomal acid lipase, esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa); Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa); Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa); | [1] D00040 D00040 💬 |
- |
- |
019 [6] 19, 90, 160, 259, 261, 310 💬 |
7 | Dextrose, unspecified form | - | - |
- |
- |
002 [18] 2 , 6 , 13, 49, 50, 56, 60, 65, 70, 75, 86, 88, 96, 160, 195, 254, 257, 299 💬 |
8 | Dupilumab | Dupilumab [5] Dupilumab; Dupilumab (blinded); Dupilumab (open-label); Dupilumab 300mg solution for injection; Dupilumab prefilled syringe; | [1] D10354 D10354 💬 |
[1] IL4R 💬 |
Cytokine-cytokine receptor interaction [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation |
051 [4] 51, 98, 160, 162 💬 |
9 | Fenamole | - | [1] D04139 D04139 💬 |
- |
- |
006 [3] 6 , 13, 160 💬 |
10 | Isotretinoin | Isotretinoin [1] Isotretinoin; | [1] D00348 D00348 💬 |
[2] RARA, RARB 💬 |
Acute myeloid leukemia [8] Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
036 [4] 36, 39, 159, 160 💬 |
11 | Lovastatin | Lovastatin [5] Lovastatin; Lovastatin 60 mg; Lovastatin ™; Lovastatin, then minocycline/lovastatin; Minocycline, then minocycline/lovastatin; | [1] D00359 D00359 💬 |
[1] HMGCR 💬 |
AMPK signaling pathway [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
006 [11] 6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬 |
12 | Lulizumab pegol | Lulizumab pegol [1] Lulizumab pegol; | - |
- |
- |
049 [3] 49, 53, 160 💬 |
13 | Oxiconazole | Oxiconazole [1] Oxiconazole; | [2] D00885 D00885
D08313 D08313 💬 |
- |
- |
160 [1] 160 💬 |
14 | Pimecrolimus | Pimecrolimus [2] Pimecrolimus; Pimecrolimus 1% cream; | [1] D05480 D05480 💬 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
160 [1] 160 💬 |
15 | Secukinumab | 150 mg double-blinded secukinumab [16] 150 mg double-blinded secukinumab; 150 mg open-label secukinumab; 300 mg double-blinded secukinumab; Secukinumab; Secukinumab (150 mg); Secukinumab (75 mg); Secukinumab (ain457); Secukinumab (ain457) 150 mg s.c.; Secukinumab 150 mg (2 injections per dose; Secukinumab 150 mg provided in 1.0 ml pre-filled syringes (pfss) for sc injection.; Secukinumab 150 mg/1 ml solution for injection; Secukinumab 150 milligram [cosentyx]; Secukinumab 150mg; Secukinumab 300 mg, s.c.; Secukinumab 300mg; Secukinumab 75 mg/0.5 ml solution for injection; | [1] D09967 D09967 💬 |
[1] IL17A 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
013 [7] 13, 37, 41, 46, 160, 269, 271 💬 |
16 | Simvastatin | Encapsulated simvastatin tablets [21] Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Other: simvastatin; Simvastatin; Simvastatin 20 mg; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg; Simvastatin 40 mg film-coated tablets; Simvastatin 40 mg tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin in relapsing remitting multiple sclerosis; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; Simvastatina; Simvastatina sandoz 40 mg comprimidos recubiertos con película efg; Simvastatine; Simvastatine sandoz 40 mg filmomhulde tabletten; Simvastatine sandoz 40mg deelbare filmomhulde tabletten; | [1] D00434 D00434 💬 |
[1] HMGCR 💬 |
AMPK signaling pathway [4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
006 [21] 6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬 |
17 | Sinecatechins | - | [1] D08997 D08997 💬 |
- |
- |
160 [1] 160 💬 |
18 | Zileuton | Zileuton [1] Zileuton; | [1] D00414 D00414 💬 |
[1] ALOX5 💬 |
Arachidonic acid metabolism [6] Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis |
085 [3] 85, 160, 164 💬 |